<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00594698</url>
  </required_header>
  <id_info>
    <org_study_id>127-005</org_study_id>
    <nct_id>NCT00594698</nct_id>
  </id_info>
  <brief_title>Familiarization and Safety Study of PB127 Ultrasound Contrast Agent</brief_title>
  <official_title>A Familiarization and Safety Study of Myocardial Perfusion Contrast Echocardiography With PB127 Ultrasound Contrast Agent in Patients With Suspected Obstructive Coronary Artery Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Point Biomedical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Point Biomedical</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate preparation and administration of PB127,&#xD;
      echocardiographic images obtained during PB127 administration, and evaluate the safety of&#xD;
      PB127.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objectives of this clinical trial are:&#xD;
&#xD;
        1. To train potential Phase 3 investigational sites in the preparation and andministration&#xD;
           of PB127&#xD;
&#xD;
        2. To train potential Phase 3 investigational sites in the acquisition of adequate images&#xD;
&#xD;
        3. To collect additional safety information regarding intravenous administration of PB127&#xD;
&#xD;
        4. To obtain a larger sample of images obtained with the Acuson Sequoia ultrasound system.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2002</start_date>
  <completion_date type="Actual">September 2003</completion_date>
  <primary_completion_date type="Actual">September 2003</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Technical adequacy and diagnostic quality of PB127 images</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compliance with image acquisition and Pb127 administration procedures</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">150</enrollment>
  <condition>Coronary Artery Disease</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PB127 for injectable suspension</intervention_name>
    <description>0.175 mg/kg diluted in 150 mL 5% Dextrose for Injection in glass bottles, to be administered as a single continuous infusion during image acquisition. Infusion time not to exceed 60 minutes</description>
    <other_name>CARDIOsphereÂ®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Able to provide written informed consent&#xD;
&#xD;
          2. Scheduled for stress echocardiography, SPECT nuclear imaging and/or coronary&#xD;
             angiography within the two weeks prior to or following Study Day 1&#xD;
&#xD;
          3. Adequate visualization of all myocardial segments in at least one imaging plane during&#xD;
             screening non-contrast echocardiogram&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Women who were pregnant or lactating&#xD;
&#xD;
          2. Known hypersensitivity or known contraindication to&#xD;
&#xD;
               1. Dipyridamole&#xD;
&#xD;
               2. Other ultrasound contrast agents&#xD;
&#xD;
               3. Blood, blood products, albumin, egg, or protein&#xD;
&#xD;
          3. Use of caffeine or xanthine containing products within the 24 hours prior to PB127 MPE&#xD;
&#xD;
          4. Frequent (&gt; 60/hour) or symptomatic ventricular ectopics at baseline&#xD;
&#xD;
          5. Atrial fibrillation&#xD;
&#xD;
          6. Permanent pacemaker or defibrillator&#xD;
&#xD;
          7. History of:&#xD;
&#xD;
               1. Complex ventricular arrhythmia&#xD;
&#xD;
               2. Chronic hepatitis&#xD;
&#xD;
               3. Liver disease characterized by one or more of the following:&#xD;
&#xD;
                    -  current jaundice&#xD;
&#xD;
                    -  elevated bilirubin &gt; upper limit of normal&#xD;
&#xD;
                    -  currently elevated hepatic enzymes &gt; 2X upper limit of normal&#xD;
&#xD;
                    -  current or previous hepatic viral infection&#xD;
&#xD;
               4. Chronic obstructive pulmonary disease (COPD) that, in the opinion of the&#xD;
                  Investigator, was significant enough to contraindicate dipyridamole&#xD;
&#xD;
               5. Bronchospastic airway disease that, in the opinion of the Investigator, was&#xD;
                  significant enough to contraindicate dipyridamole&#xD;
&#xD;
               6. Coronary artery bypass graft (CABG) within the 7 days prior to Study Day 1&#xD;
&#xD;
               7. Heart transplant&#xD;
&#xD;
               8. Q wave myocardial infarction within the 7 days prior to Study Day 1&#xD;
&#xD;
               9. Cardiac intervention or surgery within the 7 days prior to Study Day 1&#xD;
&#xD;
          8. Hypertension (systolic blood pressure [SBP] &gt;200 mmHg and diastolic blood pressure&#xD;
             [DBP] &gt;110 mmHg)&#xD;
&#xD;
          9. Hypotension (SBP &lt;90 mmHg) documented within the 24 hours prior to Study Day 1&#xD;
&#xD;
         10. Significant valvular disease&#xD;
&#xD;
               1. Severe aortic stenosis (&gt;100 mmHg peak transvalvar gradient or &lt;0.6 cm2 estimated&#xD;
                  valve area)&#xD;
&#xD;
               2. Severe mitral regurgitation (usual clinical criteria plus or minus any of the&#xD;
                  following: proximal isovelocity surface area [PISA] &gt;1 cm2, forward transmitral&#xD;
                  gradient of &gt;2 m/sec, unexplained systolic flow reversal or blunting in the&#xD;
                  pulmonary veins)&#xD;
&#xD;
               3. Severe mitral stenosis (&lt;1.0 cm2 estimated valve area)&#xD;
&#xD;
         11. Congestive heart failure (New York Heart Association [NYHA] Class IV); NYHA classes&#xD;
             are defined in Appendix D of the protocol (see Appendix 16.1.1)&#xD;
&#xD;
         12. Pulmonary edema within the 7 days prior to Study Day 1&#xD;
&#xD;
         13. Resting oxygen saturation of &lt; 90%&#xD;
&#xD;
         14. Pulmonary hypertension characterized by estimated pulmonary artery systolic pressure&#xD;
             of &gt;50 mmHg by echo or catheter criteria on Study Day 1&#xD;
&#xD;
         15. Unstable angina, Canadian Cardiovascular Society (CCS) Class IV severity, with ongoing&#xD;
             symptoms and/or ongoing infusion of intravenous nitroglycerin; CCS grading criteria&#xD;
             are provided in Appendix E of the protocol (see Appendix 16.1.1)&#xD;
&#xD;
         16. Second degree heart block or greater&#xD;
&#xD;
         17. Use of intravenous or intracoronary contrast agent within the 24 hours prior to Study&#xD;
             Day 1&#xD;
&#xD;
         18. Medical conditions or other circumstances that would significantly decrease the&#xD;
             chances of obtaining reliable data or achieving the study objectives, ie, drug&#xD;
             dependence, psychiatric disorder, dementia, or other reasons for expected poor&#xD;
             compliance with the Investigator's instructions; medical conditions, associated&#xD;
             illness, or extenuating circumstances that made it unlikely that a patient can&#xD;
             complete the clinical trial or follow-up evaluations&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexander Ehlgen, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>POINT Biomedical Corp.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Michael Morgan, MD</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heartcare, P.C.</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Scottsdale</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Long Beach VA Medical Center Cardiology Division</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90822</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California San Diego Division of Cardiology</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Francisco VA Medical Center NCIRE</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington Hospital Center Cardiovascular Research Institute</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krannert Institute of Cardiology</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Center for Cardiovascular Studies Kramer and Crouse Cardiology</name>
      <address>
        <city>Shawnee Mission</city>
        <state>Kansas</state>
        <zip>66204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Androscoggin Cardiovascular Associates</name>
      <address>
        <city>Auburn</city>
        <state>Maine</state>
        <zip>04210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maine Cardiology Associates</name>
      <address>
        <city>South Portland</city>
        <state>Maine</state>
        <zip>04106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New England Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Consultants</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Louis University Medical Center</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MidWest Cardiologist Research</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endovascular Research, LLC</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health Sciences University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Cardiovascular Institute</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin Heart</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dallas VA Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Presbyterian Hospital of Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Methodist DeBakery Heart Center Cardiovascular Imaging Institute</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Sciences Center at San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia Health System</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Mason Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harborview Medical Center Department of Cardiology</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inland Cardiology</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Cardiovascular Research Institute Spokane Cardiology</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2008</verification_date>
  <study_first_submitted>January 4, 2008</study_first_submitted>
  <study_first_submitted_qc>January 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 16, 2008</study_first_posted>
  <last_update_submitted>July 1, 2008</last_update_submitted>
  <last_update_submitted_qc>July 1, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 3, 2008</last_update_posted>
  <responsible_party>
    <name_title>Tom Ottobonie, PhD/Chief Operating Officer</name_title>
    <organization>POINT Biomedical Corp.</organization>
  </responsible_party>
  <keyword>Perfusion</keyword>
  <keyword>Echocardiography</keyword>
  <keyword>Cardiac angiography</keyword>
  <keyword>SPECT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

